Pulmonary hypertension is a hemodynamic condition shared by very different diseases, in which increased pressure in the pulmonary circulation may result from elevated left heart pressures, loss or alteration of the pulmonary vascular bed, hypoxia, chronic arterial obstructions or combined mechanisms. The pressure value alone neither identifies the cause nor establishes which treatment is appropriate. Distinguishing these processes is essential because a therapy that is beneficial in one form may be ineffective or harmful in another.
The term other forms is descriptive and does not correspond to a sixth group in the international classification. Here it includes conditions other than adult PAH considered as primary or associated arterial vascular disease, as well as a distinct disorder of neonatal circulatory transition. Pulmonary hypertension therefore does not automatically mean pulmonary arterial hypertension, and the adjective "secondary", although common in clinical language, does not replace a precise etiologic definition.
Pulmonary arterial pressure depends on the interaction between cardiac output, vascular resistance and downstream pressure in the circulation. An increase may accompany elevated left atrial pressure, increased resistance or very high blood flow. Consequently, two people with the same mean pressure may have different mechanisms and prognoses. The right ventricle is also affected by arterial stiffness and pulsatile load, which are not fully represented by calculated resistance alone.
In adults, pulmonary hypertension is defined at catheterization by a mean pulmonary arterial pressure greater than 20 mmHg. The precapillary profile requires pulmonary arterial wedge pressure not exceeding 15 mmHg and pulmonary vascular resistance greater than 2 Wood units. In the postcapillary profile, wedge pressure exceeds 15 mmHg: resistance not exceeding 2 identifies isolated postcapillary pulmonary hypertension, whereas higher values indicate a combined pre- and postcapillary component. These definitions describe hemodynamics and must be integrated with the clinical cause.
Wedge pressure measurement deserves particular attention when obesity, substantial respiratory variations, intensive diuresis or mixed diseases make interpretation ambiguous. A technically flawed measurement can move a patient from one therapeutic pathway to another. In selected cases, provocative testing at expert centers may clarify left heart disease that is not evident at rest. Such tests should not be added indiscriminately: they must address a question whose answer would change management.
Pulmonary hypertension due to left heart disease is related to elevated left heart filling pressures and includes heart failure with reduced or preserved ejection fraction, valvular heart diseases and other cardiac abnormalities. Backward transmission of pressure may initially predominate over vascular injury; over time, some patients develop remodeling that further increases resistance. The emergence of this component does not automatically turn the condition into group 1 PAH.
Age, atrial fibrillation, left atrial enlargement, obesity and metabolic comorbidities may support a cardiac phenotype, but no single feature resolves every case. Assessment must include the valves, systolic and diastolic function, volume status and quality of invasive measurements. Treatment targets the cardiac disease and congestion; PAH medications are not routinely indicated. Negative trials or evidence of harm explain why the reasoning cannot be reduced to "high pressure, therefore pulmonary vasodilation".
In pulmonary hypertension due to lung diseases, destruction of the capillary bed, inflammation, vascular compression and remodeling may all contribute. COPD, emphysema, interstitial lung diseases and combinations of fibrosis and emphysema produce different phenotypes. The relationship between respiratory disease severity and vascular impairment is not always linear: particularly severe dyspnea, very low DLCO or signs of right heart failure may suggest clinically significant vascular involvement.
Pulmonary hypertension due to hypoxia highlights a mechanism spanning several conditions. Hypoxic vasoconstriction, which is useful when it redirects blood flow away from poorly ventilated lung units, can become a widespread burden if the stimulus affects large areas or persists over time. Hypoventilation and exposure to high altitude require specific assessment. Isolated obstructive sleep apnea should not be considered a sufficient explanation for every case of significant pulmonary hypertension, particularly when obesity hypoventilation, heart disease or lung disease coexist.
Treatment of respiratory disease and correction of hypoxemia when indicated remain central. Catheterization is not necessary for every mildly elevated echocardiographic pressure estimate, but becomes useful if it clarifies a severe phenotype, a possible alternative diagnosis or a therapeutic or transplantation option. In lung diseases, vascular severity may also be defined by resistance; a PVR greater than 5 Wood units identifies a subgroup requiring particular specialist attention. This does not automatically authorize the use of any vasodilator.
Evidence for medical treatment depends on the lung disease. The benefit observed with inhaled treprostinil in pulmonary hypertension associated with interstitial lung disease cannot be extrapolated to COPD; the PERFECT trial in the latter setting was stopped because of safety concerns and an unfavorable benefit–risk balance. Even an inhaled medication must be evaluated in the population in which it was studied, considering regulatory indications and local access. This distinction is more useful than a generic rule either favoring or opposing every medication throughout group 3.
Chronic thromboembolic pulmonary hypertension results from persistent organized thrombotic material, associated to varying degrees with small-vessel disease. It is not simply an acute embolism that lasts longer and can be identified even without a previously documented embolic episode. Persistent dyspnea after embolism or otherwise unexplained pulmonary hypertension should therefore prompt consideration of this possibility.
Ventilation/perfusion scintigraphy retains an important role in ruling out the disease, while CT pulmonary angiography and additional vascular imaging define the distribution and features of obstructions. Operability cannot be inferred from a single image or pressure value alone: it requires expert multidisciplinary assessment. Pulmonary endarterectomy, balloon angioplasty and medical therapy can be integrated into an individual strategy; long-term anticoagulation is a fundamental component of CTEPH management.
Recognition of the mechanical component is crucial because it may open up treatment possibilities very different from those for PAH. Conversely, prescribing a vasodilator alone without evaluating whether the lesions are accessible may delay a potentially more effective option. Symptomatic chronic thromboembolic disease without pulmonary hypertension at rest also exists: in these cases too, the relationship between symptoms and obstructions must be demonstrated and decisions are selective.
Multifactorial pulmonary hypertension includes group 5 conditions in which several processes or incompletely understood mechanisms contribute to the clinical picture. Hematologic diseases, sarcoidosis and certain metabolic or systemic conditions may involve arteries, veins, lung parenchyma and the heart. Group 5 is not, however, a catch-all category to be used whenever two comorbidities coexist: the underlying disease must be identified and the predominant mechanism described whenever possible.
In these patients, individualization concerns diagnosis first and foremost. For example, the same systemic setting can produce vascular disease, extensive fibrosis, vascular compression or left heart disease, with different therapeutic implications. Evidence supporting PAH medications is heterogeneous and often limited; treating the cause and multidisciplinary discussion therefore carry particular weight. Elevated pressure does not justify presuming a single shared biological mechanism.
Persistent pulmonary hypertension of the newborn, by contrast, is a syndrome in which adaptation of the pulmonary circulation at birth fails or remains inadequate. Elevated pulmonary vascular resistance promotes right-to-left shunting through fetal communications and hypoxemia, in association with respiratory disease, abnormal vascular development or other factors. In the clinical classification, it is placed in group 1, although it requires pathophysiologic and therapeutic reasoning distinct from that used for chronic PAH in adults. Its inclusion in this collection does not change that classification.
Neonatal assessment requires prompt echocardiography to characterize shunts and ventricular function and exclude critical congenital heart disease. Oxygenation, lung recruitment, circulatory support and selective vasodilation are tailored to each newborn's physiology. Adult invasive thresholds and algorithms cannot simply be transferred to the postnatal transition. Urgency is governed chiefly by stability and hypoxemia, not by the need to complete the same diagnostic workup used in adults.
Across all these conditions, comorbidity changes the probability of diagnoses without negating the value of a complete assessment. A patient with COPD can also have CTEPH; a person with heart failure with preserved ejection fraction may also have significant respiratory disease. The aim is not to attribute every abnormality to the most common group, but to determine which components have been demonstrated, which predominates and which can be modified. A partial explanation for dyspnea does not eliminate the need to look for others when severity and findings are discordant.
Reversibility varies according to mechanism and time. A congestion-related component may decrease after treatment of the left heart, while established remodeling may persist; organized obstruction may be amenable to intervention, while associated small-vessel disease requires an additional strategy. Outcomes therefore cannot be assessed solely immediately after treatment. Subsequent follow-up must verify whether pressure, resistance, symptoms and right ventricular function improve consistently or reveal a residual component.
Adult evaluation proceeds from clinical suspicion to echocardiographic probability, identification of the cause and invasive confirmation when indicated. History and physical examination help identify cardiac disease, lung disease, thromboembolism or systemic illness. Pulmonary function tests including DLCO, thoracic imaging, perfusion studies and targeted tests help establish a phenotype. Catheterization addresses hemodynamic uncertainty and decisions requiring reliable data; it is not an end in itself independent of the clinical problem.
Discordance between findings is often informative: severe right ventricular overload with modest respiratory abnormalities, marked hypoxemia with nearly normal spirometry or wedge pressure inconsistent with cardiac imaging calls for reassessment. Several mechanisms may coexist, and their relative contributions may change over time. The initial classification must therefore be open to revision without treating every change as an error when new measurements demonstrate a different phenotype.
The right ventricle is a common determinant of outcomes, but risk scores validated in PAH cannot automatically be applied to every other group. Prognosis and response are assessed in conjunction with the causative disease: left ventricular function and valves in group 2, respiratory reserve in group 3, accessibility of lesions in CTEPH and activity of systemic disease in group 5. Worsening symptoms also requires a search for infection, arrhythmia, anemia and changes in volume status.
The therapeutic strategy combines mechanism, severity and feasible interventions. It may involve optimizing heart failure treatment, correcting a valvular lesion, treating hypoventilation and hypoxemia, removing or dilating vascular obstructions or addressing a systemic disorder. Oxygen, diuretics, rehabilitation and transplantation assessment have varying indications and must be integrated with causal treatment. Continuity between diagnosis, intervention and reassessment makes it possible to determine whether treatment truly changes functional capacity, right ventricular function and quality of life.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.